Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial.
about
Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophiliaProphylaxis for venous thromboembolic disease in pregnancy and the early postnatal periodAntithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunctionAntithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunctionProphylaxis for venous thromboembolic disease in pregnancy and the early postnatal periodVTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesPrevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin: a meta-analysisHeparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial.Low-molecular-weight heparin for prevention of placenta-mediated pregnancy complications: protocol for a systematic review and individual patient data meta-analysis (AFFIRM).The diagnosis and treatment of hypertensive disorders of pregnancy: new findings for antenatal and inpatient careLow-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT.Evaluating patient values and preferences for thromboprophylaxis decision making during pregnancy: a study protocol.Coagulation and placenta-mediated complications.Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a prior history - an open-label randomised trial (the EPPI trial): study protocol.Preeclampsia - Aetiology, Current Diagnostics and Clinical Management, New Therapy Options and Future Perspectives.Heparin rescues factor V Leiden-associated placental failure independent of anticoagulation in a murine high-risk pregnancy model.Short- and long-term strategies for the management of hypertensive disorders of pregnancy.Outcomes in women receiving low-molecular-weight heparin during pregnancy.Management of subsequent pregnancy after antepartum stillbirth. A review.Low molecular weight heparin in obstetric care: a review of the literature.In vitro evidences of heparin's effects on embryo implantation and trophoblast development.Thrombosis in women: what are the knowledge gaps in 2013?Antithrombotic treatment for pregnancy complications: which path for the journey to precision medicine?Overview of low molecular weight heparin for preventative treatment of adverse obstetric outcomes related to abnormal placentation.Infants at risk of cerebral palsy: a systematic review of outcomes used in Cochrane studies of pregnancy, childbirth and neonatology.LMWH to prevent placenta-mediated pregnancy complications: an update.High-risk pregnancy and the rheumatologist.SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014.Enhancement of trophoblast differentiation and survival by low molecular weight heparin requires heparin-binding EGF-like growth factor.Aspirin vs Heparin for the Prevention of Preeclampsia.Heparin promotes soluble VEGF receptor expression in human placental villi to impair endothelial VEGF signaling.Report of the Obstetric APS Task Force: 13th International Congress on Antiphospholipid Antibodies, 13th April 2010.Identification of high-risk patients for adverse pregnancy outcome based on multivariate logistic regression analysis at 20-23 gestational weeks.Is thrombophilia associated with placenta-mediated pregnancy complications? A prospective cohort study.Exploring the role of antithrombin replacement for the treatment of preeclampsia: a prospective randomized evaluation of the safety and efficacy of recombinant antithrombin in very preterm preeclampsia (PRESERVE-1).Low molecular weight heparin treatment and impact of inherited thrombophilia type in pregnancies with previous adverse outcome.The HMGB1/RAGE Pro-Inflammatory Axis in the Human Placenta: Modulating Effect of Low Molecular Weight Heparin.Prophylactic Low Molecular Weight Heparin Improving Perinatal Outcome in Non-thrombophilic Placental-Mediated Complications.Effects of low molecular weight heparins and unfractionated heparin on viability of human umbilical vein endothelial cells.Recurrence and severity of abnormal pregnancy outcome in patients treated by low-molecular-weight heparin: a prospective pilot study.
P2860
Q24194917-498C615D-A74E-44E7-8D2C-58B03FB8FEA7Q24200433-41622209-0B05-4A1C-B46C-4A36503C1267Q24201073-E0BC7D5E-65D4-4574-9803-ADDFFB4446E4Q24235012-3F662D8A-201C-43C6-81C6-7FFF8F8894BDQ24235476-E4E2404E-102E-4C70-82F9-10B79D0608C3Q24632982-C72D85C3-B10B-4D86-9C01-199F3E96119AQ26781800-9E038F52-1743-4B50-B4C8-9E7F3E68D33AQ30512857-258DB6F1-9A49-4E12-BFC5-E7225ED05D98Q30833556-A0787F5D-230E-4271-A34F-1D4362088087Q30973898-18632940-0F42-481A-BD2A-CEC6FE94610DQ34236115-CFA8F83C-4F2B-449E-A23E-0298BAEB40E8Q34286102-510CB46A-FD31-47D6-B165-3EE1A180BFAAQ34463447-88E70F90-1887-47CC-B906-51506B3F6C64Q36201389-853CC9AC-C63F-4720-98CE-7BE3B260FD93Q36295102-D79CDDAB-D989-408B-8E56-E51D67791BB4Q37634740-CA21F29B-64E3-4D7E-8789-7C4696C701A2Q37642835-EA9ED919-B49A-4B7B-8E89-2AF1EE8C0F1BQ37731116-61AD4A7F-782B-4B8E-9F47-9B2447CABD47Q37760935-A3198B5A-9615-4DB9-92E2-6683C81E9BAEQ37892215-2AA454A5-F682-49E1-B368-269F85FA3FE2Q37989428-EEBEC2C5-281A-4B15-AF57-5A0F25A96B34Q38117735-39B19B25-87BE-488E-81A2-3DA8B4608D4BQ38193203-665C42FF-7AEB-4E96-9664-07FAD5B00C1BQ38206136-6B882C64-4BCC-4373-A417-89F10F9D4A20Q38256857-BF51BA23-86B1-4453-90CF-BE16720C4E7DQ38268419-63C30310-84C5-4E78-9440-6B86FEBA707FQ38283472-DE414DA4-0A99-4E02-8152-37DFCAE06717Q38594110-76659B1B-7D1E-45D6-B044-95E5BC178D42Q38707996-2BFA5513-55FB-48EC-9E8E-7F2D9D7523DAQ38850828-FD5715D4-ABDD-4B97-AA6E-CC16B9E13DEBQ39699823-0C04813F-4ED8-4123-B2C7-2D0D03203742Q39785052-43FAD5D4-BA36-40E8-9459-FAD7306C7006Q43789942-927EC061-095B-4CA5-A7B9-1F879571DBD4Q44113152-8817FCD5-0767-4F56-9841-F9DE52A488C0Q46877462-DE854E63-491A-466D-81DA-09F7559C7BD0Q47175145-0FB6E94B-37BF-457A-98D3-24100D3BA14EQ47176251-BE626C1D-5389-4ADA-9980-9282055D12F8Q47259579-4F33F19B-A465-48E9-ADC7-6E28DCF44C2CQ47284780-0CD7D77A-7B84-4C47-9DFD-F1A9BC9E33EDQ47341597-6D9A3A31-980E-4FB1-8ACA-743F7A33FB5F
P2860
Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Dalteparin for the prevention ...... t randomized controlled trial.
@ast
Dalteparin for the prevention ...... t randomized controlled trial.
@en
type
label
Dalteparin for the prevention ...... t randomized controlled trial.
@ast
Dalteparin for the prevention ...... t randomized controlled trial.
@en
prefLabel
Dalteparin for the prevention ...... t randomized controlled trial.
@ast
Dalteparin for the prevention ...... t randomized controlled trial.
@en
P2093
P2860
P1476
Dalteparin for the prevention ...... t randomized controlled trial.
@en
P2093
R Gauthier
P2860
P356
10.1111/J.1538-7836.2008.03230.X
P577
2008-11-20T00:00:00Z